2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2018-4-2-0-41419GeneticsMOLECULAR AND GENETIC CHARACTERISTICS OF PATIENTS WITH HYPERPLASIA AND ENDOMETRIC POLYPSMOLECULAR AND GENETIC CHARACTERISTICS OF PATIENTS WITH HYPERPLASIA AND ENDOMETRIC POLYPSDemakovaNatalia A.DemakovaNatalia A.demakova05@gmail.com20184200

Background. Hyperplastic processes of the endometrium (GGE) are among the most frequent gynecological diseases, leading to a loss of reproductive function and a decrease in the quality of life of women, and are the basis for the formation of malignant endometrial tumors. The aim of the study. To study the involvement of cytokine candidate genes in the formation of endometrial hyperplasia and polyps. Materials and methods. The sample for the study was 243 women with hyperplastic endometrial processes and 249 women in the control group. Samples of patients and control included women of Russian nationality. All patients with GGE and women of the control group were subjected to genotyping of nine molecular-genetic markers by the polymerase chain reaction of DNA synthesis: -308 G/A TNFα, +252 A/G Ltα, +36 A/G TNFR1, + 1663G/A TNFR2, 403A/G RANTES, A/G I-TAC (rs4512021), + 1931A/T MIP1β, C/G MCP1 (rs2857657), -801G/A SDF1. Results. It was found that with the development of endometrial hyperplasia, fourteen combinations of polymorphic markers -308 G/A TNFα, +252 A/G Ltα, +36 A/G TNFR1, +1663A/G TNFR2, +1931 A/T MIP1β, C/G MCP1 (rs2857657), -801 G/A SDF1. These combinations increase the risk of developing endometrial hyperplasia (OR = 2.05-4.11). The formation of endometrial polyps is associated with three combinations of genetic variants: +252 AA Ltα and +36 AG TNFR1 (OR = 2.22); +252 AA Ltα and + 36 A TNFR1 (OR = 1.71); +36 A TNFR1 and -801 GG SDF1 (OR = 1.70). Conclusion. Combinations of polymorphic loci 308 G/A TNFα, +252 A/G Ltα, +36 A/G TNFR1, +1663A/G TNFR2, +1931 A/T MIP1β, C/G MCP1 (rs2857657), -801 G/A SDF1 are associated with the development of endometrial hyperplasia, and the combinations of the polymorphisms +252 A/G Ltα, +36 A/G TNFR1, -801 G/A SDF1 are associated with the development of endometrial polyps.

Background. Hyperplastic processes of the endometrium (GGE) are among the most frequent gynecological diseases, leading to a loss of reproductive function and a decrease in the quality of life of women, and are the basis for the formation of malignant endometrial tumors. The aim of the study. To study the involvement of cytokine candidate genes in the formation of endometrial hyperplasia and polyps. Materials and methods. The sample for the study was 243 women with hyperplastic endometrial processes and 249 women in the control group. Samples of patients and control included women of Russian nationality. All patients with GGE and women of the control group were subjected to genotyping of nine molecular-genetic markers by the polymerase chain reaction of DNA synthesis: -308 G/A TNFα, +252 A/G Ltα, +36 A/G TNFR1, + 1663G/A TNFR2, 403A/G RANTES, A/G I-TAC (rs4512021), + 1931A/T MIP1β, C/G MCP1 (rs2857657), -801G/A SDF1. Results. It was found that with the development of endometrial hyperplasia, fourteen combinations of polymorphic markers -308 G/A TNFα, +252 A/G Ltα, +36 A/G TNFR1, +1663A/G TNFR2, +1931 A/T MIP1β, C/G MCP1 (rs2857657), -801 G/A SDF1. These combinations increase the risk of developing endometrial hyperplasia (OR = 2.05-4.11). The formation of endometrial polyps is associated with three combinations of genetic variants: +252 AA Ltα and +36 AG TNFR1 (OR = 2.22); +252 AA Ltα and + 36 A TNFR1 (OR = 1.71); +36 A TNFR1 and -801 GG SDF1 (OR = 1.70). Conclusion. Combinations of polymorphic loci 308 G/A TNFα, +252 A/G Ltα, +36 A/G TNFR1, +1663A/G TNFR2, +1931 A/T MIP1β, C/G MCP1 (rs2857657), -801 G/A SDF1 are associated with the development of endometrial hyperplasia, and the combinations of the polymorphisms +252 A/G Ltα, +36 A/G TNFR1, -801 G/A SDF1 are associated with the development of endometrial polyps.

hyperplastic processes of the endometriumpolyps of the endometriumgenetic polymorphismhyperplastic processes of the endometriumpolyps of the endometriumgenetic polymorphismСписок литературыDobrokhotova Yu. Metody lecheniya atipicheskoy giperplazii endometriya [Methods of treatment of atypical endometrial hyperplasia]. Lechebnoe delo. 2011;1:71-79. Russian.Zaporozhan VN, Tatarchuk TF, Dubinina VG, Kosey NV. Sovremennaya diagnostika i lecheniye giperplasticheskikh protsessov endometriya [Modern diagnostics and treatment of endometrial hyperplastic processes]. Reproduktivnaya endokrinologiya. 2012;1:5-12. Russian.Kiselev VI. Giperplasticheskiye protsessy organov zhenskoy reproduktivnoy sistemy: teoriya i praktika [Hyperplastic processes of the organs of the female reproductive system: theory and practice]. Moscow: Medpraktika-M; 2011. 467 p. Russian.Lysenko OV. Novyye podkhody k terapii giperplasticheskikh protsessov i polipov endometriya [New approaches to the therapy of hyperplastic processes and endometrial polyps]. Tsitokiny i vospaleniye. 2011;10(4):125-129. Russian.Rebrova OYu. Statisticheskiy analiz meditsinskikh dannykh: primeneniye paketa prikladnykh programm STATISTICA. Moscow: Media Sphera; 2006. 305 p. Russian.Sidorova I, Unanyan A, Vlasov R, Evtina I, Karpov D. Giperplasticheskiye protsessy endometriya: osobennosti kliniki i terapii [Hyperplastic processes of the endometrium: features of the clinic and therapy]. Vrach. 2011;6:58-60. Russian.Strizhakov AN. Dobrokachestvennyye zabolevaniya matki [Benign uterine diseases]. Moscow: GEOTAR-Media; 2011. 281 p. Russian.Tkachenko LV, Sviridova NI, Isayeva LV, Bogatyreva LN. Kombinirovannyy metod lecheniya retsidiviruyushchikh giperplasticheskikh protsessov endometriya u zhenshchin s metabolicheskim sindromom [Combined method of treatment of recurrent endometrial hyperplastic processes in women with metabolic syndrome]. Ural'skiy meditsinskiy zhurnal. 2011;4(82):72-75. Russian.Chernukha GE, Dumanovskaya MR, Burmenskaya OV, et al. Ekspressiya genov, reguliruyushchikh apoptoz, pri raznykh tipakh giperplazii endometriya i endometrioidnoy [Expression of the genes that regulate apoptosis, with different types of endometrial hyperplasia and endometrial]. Akusherstvo i gynekologia. 2013;1:63-69. Russian. Sheshukova NA. Giperplasticheskiye protsessy endometriya: osobennosti proliferativnoy aktivnosti pri sochetanii s khronicheskim endometritom [Hyperplastic processes of the endometrium: features of proliferative activity in combination with chronic endometritis]. Akusherstvo, gynekologia i reproductsia. 2011;3:10-15. Russian.Chandra V, Fatima I, Saxena R, Kitchlu S, Sharma S, Hussain M, Hajela K, Bajpai P, Dwivedi A. Apoptosis induction and inhibition of hyperplasia formation by 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b)pyran in rat uterus. Am. J. Obstet. Gynecol. 2011;205(4):362.Daya D. Endometrial hyperplasia and carcinoma with superimposed secretory changes: a double whammy. Int. J. Gynecol. Pathol. 2014;33(2):105-106.Eritja N, Mirantes C, Llobet D, Yeramian A, Bergadà L, Dosil M, Domingo M, Matias-Guiu X, Dolcet X. Long-term estradiol exposure is a direct mitogen for insulin/EGF-primed endometrial cells and drives PTEN loss-induced hyperplasic growth. Am. J. Pathol. 2013;183(1):277-287.Favorov A, Lvovs D, Speier W, Parmigiani G, Ochs M. OnionTree XML: A Format to Exchange Gene-Related Probabilities. J. Biomol. Struct. Dyn. 2010;29(2):417-423.Giuntoli RL, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow RE. Stage Inoninvasive andminimallyinvasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int. J. Gynecol. Cancer. 2012;22(2):273-279.Goncharenko VM, Beniuk VA, Kalenska OV, Demchenko OM, Spivak MY, Bubnov RV. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in fertile age women. EPMA J. 2013;4(1):24.Hvingel B, Lieng M, Roald B, Оrbo A. Vascular markers CD31, CD34, actin, VEGFB, and VEGFR2, are prognostic markers for malignant development in benign endometrial polyps. Open J. Obstet. Gynecol. 2012;2(1):18-26.Lacey JrJV, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DА, Chatterjee N, Langholz B. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J. Clin. Oncol. 2010;28(5):788-792.Miller B. A potential prognostic factor in adenocarcinoma of the endometrium. Gynecol. Oncol. 1994;54(2):137-141.Munro MG, Dickersin K, Clark MA, Langenberg P, Scherer RW, Frick KD. The Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding: summary of an Agency for Health Research and Quality-sponsored randomized trial of endometrial ablation versus hysterectomy for women with heavy menstrual bleeding. Menopause. 2011;18(4):445-452.Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Robert H, Zaino R, Mutter GL. Management of endometrial precancers. Obstet. Gynecol. 2012;120(5):1160-1175.Truskinovsky AM. Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge. Int. J. Gynecol. Pathol. 2014;33(2):107-113.Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, Cushman M, Strickler HD, Kaplan RC, Wassertheil-Smoller S, Scherer PE. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol. Biomarkers Prev. 2011;20(5):971-977.Witkiewicz AK, McConnell T, Potoczek M, Emmons RV, Kurman RJ. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Hum. Pathol. 2010;41(1):26-32.